Antibacterial agent 350 TFA is a membrane stabilizer/disruptor with antibacterial activity. Antibacterial agent 350 TFA reduces glucose-induced efflux efficiency and slightly impairs outer membrane stability. Antibacterial agent 350 TFA significantly decreases the bacteriostatic MIC 50 of Ceftazidime or Ciprofloxacin, but increases the MIC 50 of Amikacin. Antibacterial agent 350 TFA can be used for the research of Pseudomonas aeruginosa infections [1].
In Vitro, Antibacterial agent 350 (compound 3) (15.6-125 μM; 60 min) TFA causes slight outer membrane permeabilization in Pseudomonas aeruginosa PA01, but its primary activity is potent efflux inhibition, which is significantly greater than its permeabilization effect at all tested concentrations[1].
References:
[1]. Borselli D, et al. Polyamino-isoprenic derivatives block intrinsic resistance of P. aeruginosa to doxycycline and chloramphenicol in vitro[J]. PLoS One, 2016, 11(5): e0154490.
In Vitro, Antibacterial agent 350 (compound 3) (15.6-125 μM; 60 min) TFA causes slight outer membrane permeabilization in Pseudomonas aeruginosa PA01, but its primary activity is potent efflux inhibition, which is significantly greater than its permeabilization effect at all tested concentrations[1].
References:
[1]. Borselli D, et al. Polyamino-isoprenic derivatives block intrinsic resistance of P. aeruginosa to doxycycline and chloramphenicol in vitro[J]. PLoS One, 2016, 11(5): e0154490.